Baxter exits vaccines business as it preps for biopharma spinout

By Dan Stanton contact

- Last updated on GMT

A dry fracture of a Vero cell exposing the contents of a vacuole where Coxiella burnetii (the Bacteria that cause Q Fever) are growing
A dry fracture of a Vero cell exposing the contents of a vacuole where Coxiella burnetii (the Bacteria that cause Q Fever) are growing

Related tags: Influenza vaccine, Influenza

Baxter has sold its pandemic flu portfolio and Vero cell technology to Nanotherapeutics in preparation for the launch of its haematology and oncology-based spinout company Baxalta. 

Originally announced in March​, Baxter’s decision to separate its biopharma business was driven by growth opportunities in the areas of haemotology, oncology and biosimilars, and in preparation for the launch of ‘Baxalta’​ next year, the firm has divested its Vero cell vaccine platform.

Spokesperson Kellie Hotz told Biopharma-Reporter.com the sale to Florida-based development and biomanufacturing firm Nanotherapeutics includes Baxter’s pandemic flu vaccines Celvapan, Vepacel and Preflucel, all of which are manufactured from the Vero cell platform.

 “[The] Vero cell platform is an advanced cell-based technology for production of vaccines that offers greater scale and responsiveness to new and emerging pandemics, such as avian flu, compared to traditional egg-based culture technologies,”​ she said.

“The technology uses a well-established cell line to produce vaccines in a unique serum protein-free medium, significantly reducing production time.”

Nanotherapeutics is also acquiring Baxter’s production facility in Bohumil, Czech Republic, and will take on around 40 employees who have been maintaining the site, in accordance with their employment contracts, she added.

Vaccine Exit

With this sale, Baxter has completed its exit from vaccine production following the sale in July​ of its NeisVac-C and FSME-IMMUN/TicoVac vaccines – used against meningitis and tick-borne encephalitis (TBE) respectively – and a facility in Austria to Pfizer for $635m (€510m).

The firm will now focus “on core areas of expertise – immunology, hematology/oncology and technology platforms such as gene therapy and biosimilars – as [it] prepares to become an independent global biopharmaceutical company in mid-2015,”​ Hotz explained.

In 2013​, Baxter’s vaccine division reported sales of $292m, up 15% on the previous year but still a small percentage of the overall $6.6bn worth of revenue brought in by the BioScience business. Sales of haemophilia products were $3.4bn, while biotherapeutics clocked in $2.1bn. 

Baxter is not the only Big Biopharma to have divested its vaccines business. Swiss Giant Novartis recently divested its flu vaccine division to CSL Limited for $275m​, while GlaxoSmithKline is on the verge of buying​ the rest of its vaccines business for around $7bn.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars